Purpose-To investigate thermal dose volume (TDV) and non-perfused volume (NPV) of magnetic resonance-guided focused ultrasound (MRgFUS) treatments in patients with soft tissue tumors, and describe a method for MR thermal dosimetry using a baseline reference.Materials and Methods-Agreement between TDV and immediate post treatment NPV was evaluated from MRgFUS treatments of five patients with biopsy-proven desmoid tumors. Thermometry data (gradient echo, 3T) were analyzed over the entire course of the treatments to discern temperature errors in the standard approach. The technique searches previously acquired baseline images for a match using 2D normalized cross-correlation and a weighted mean of phase difference images. Thermal dose maps and TDVs were recalculated using the matched baseline and compared to NPV.Results-TDV and NPV showed between 47%-91% disagreement, using the standard immediate baseline method for calculating TDV. Long-term thermometry showed a nonlinear local temperature accrual, where peak additional temperature varied between 4-13°C (mean = 7.8°C) across patients. The prior baseline method could be implemented by finding a previously acquired matching baseline 61% ± 8% (mean ± SD) of the time. We found 7%-42% of the disagreement between TDV and NPV was due to errors in thermometry caused by heat accrual. For all patients, the prior baseline method increased the estimated treatment volume and reduced the discrepancies between TDV and NPV (P = 0.023).Conclusion-This study presents a mismatch between in-treatment and post treatment efficacy measures. The prior baseline approach accounts for local heating and improves the accuracy of thermal dose-predicted volume.Magnetic resonance-guided focused ultrasound (MRgFUS) has been used in clinical trials to ablate soft tissue tumors such as breast tumors, uterine fibroids, and prostate tumors. Some of these trials aimed to show safety and feasibility through partial tumor ablation. [1][2][3][4][5] More recently, patient studies have targeted total tumor volume ablation, including large uterine Total tumor ablation demands a highly accurate method to assess treatment efficacy. MR thermometry-derived thermal dose mapping is the primary method used to assess tumor ablation during an MRgFUS procedure. 9 MR-derived proton resonance frequency shift (PRF) thermometry provides a change in temperature, which is then used to calculate thermal dose; neither absolute temperature nor absolute dose are calculated using these methods. 10 Because these are not absolute measurements, the standard method does not account for local accumulation of heat over the course of a treatment, which can cause errors in thermometry, and thus, errors in the estimated thermal dose delivered to tissue (Fig. 1). 11,12 Underestimation of thermometry and thermal dose may result in unnecessary additional sonications of tissue that has already been ablated through sonication of adjacent areas; these extra sonications provide no benefit, while increasing risks to the patient, such ...